Thursday, 28 April 2016

Competition for Canbex




As you may know we are trying to develop a treatment for spasticity. Baclofen is the usual go to drug, but it is not without its problems. One is the Zombie effect because it is very sedating because it is sedative, because it inhibits nerve function making muscle weakness and having cognitive effects. 

It also has a low binding affinity for its target the GABA B receptor. So you need high blood/brain levels for it to work. 

Next the other problem it has a short half life = the time taken for half of the drug to disappear. This means that the drug is gone within 8hours.

This means that it can't get you through the night. Therefore you have to wake up. to dose in the night or you are going to wake up with stiffies...yet stiff legs and hands. 

So you have a peak and a trough in drug levels meaning cogfog to maintain therapy or if you try avoid the cogfog it is an "on" and "off" with the drug working. 

In this study presented at the AAN they have taken baclofen and re-formulated it to give a slow release to avoid the peaks and the troughs but to create a longer half life, so you can have a twice a day pill. In this study they show that the long-life pill is better than placebo but no different from baclofen and it drops the levels of side effects.

So if this drug makes it it this creates competition for our drug, if our drug every makes it. 

Our claim is not that it will work better than current drugs, it is that that it will avoid the side-effects e.g. sedation of current drugs. 

How does it do this? ....Magic?.....You will soon find out.

If you fit the profile and are interested in participating in our trial of VSN16R and can get to...or are willing to go to London (UCL or Barts), Liverpool or Sheffield, you can contact one of the centres (CLICK).

The study will last less than 1 month.


6 comments:

  1. Effect "zombie" is one of the side effects that I did not like to have when he took Gabapentin and FlunarizineEffect "zombie" is one of the side effects that I didn't like to have when I took Gabapentin or Flunarizine...


    If all goes well with VSN16R, ie if it passes well in all phases (and I hope so be it, hoping it), how long or so it would take for him to get marketing?

    ReplyDelete
  2. I take three of these a day and YES they DO catch up.

    I started taking Tecfidera near a year ago. After ramping up to full dosing I started getting these incredible headaches. Hospitalized me in fact. Never had this before. Put on Baclofen and it takes care of them. I'd come off Tecfidera and then started come off the Baclofen but the headaches started coming back.

    These headaches are debilitating, not run of the mill... brutal.

    So, back on the Tecfidera.

    A bit over a month ago we tried backing me off the Baclofen. Full dose in the morning, half at afternoon then full before bed. I could feel the headache coming back on.

    Its SO weird as I never had this before I'd started the Tecfidera treatment.

    ReplyDelete
  3. Tuesday, 5 April 2016




    ResearchSpeak: rituxumab vs. fingolimod post-natalizumab




    Dear Prof. mouse,

    Could you please provide citation for 5 cases of PML in Gilenya without prior Natalizumab use per your post below:

    When is real-life evidence good enough to change clinical practice? #ResearchSpeak #MSBlog #MSResearch.

    Thanks!


    ReplyDelete
    Replies
    1. Sorry No...maybe profG will.It was his post and he knows the source, maybe this is I do not keep up with every PML case it may be in a paper or maybe the grapevine

      Delete
  4. How about a USA trial at ucdavis, Sacramento?

    ReplyDelete
    Replies
    1. I think I would welcome people from all over the world so the study can get recruited quickly and then we will know the result good or bad, but it is a UK thing and it would cost more to do this internationally. This exercise has made me appreciate more, what big pharma does in getting these things finished on time.

      Delete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.